Susquehanna International Group
TVRD

Susquehanna International Group’s Tvardi Therapeutics TVRD Stock Holding History

Susquehanna International Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-39,262
Closed -$721K – 13704
2024
Q4 		$721K Buy
39,262
+35,719
+1,008% +$389K ﹤0.01% 7750
2024
Q3 		$39.3K Sell
3,543
-1,619
-31% -$19K ﹤0.01% 11464
2024
Q2 		$47.9K Buy
5,162
+3,445
+201% +$82.2K ﹤0.01% 11429
2024
Q1 		$56.3K Buy
1,717
+448
+35% +$11.6K ﹤0.01% 11517
2023
Q4 		$33.9K Sell
1,269
-6,706
-84% -$278K ﹤0.01% 11846
2023
Q3 		$482K Buy
7,975
+795
+11% +$74.6K ﹤0.01% 8310
2023
Q2 		$731K Buy
7,180
+5,673
+376% +$781K ﹤0.01% 7415
2023
Q1 		$266K Buy
+1,507
New +$505K ﹤0.01% 9982
2022
Q4 		– Sell
-1,870
Closed -$710K – 13922
2022
Q3 		$630K Sell
1,870
-199
-10% -$72.1K ﹤0.01% 7853
2022
Q2 		$680K Buy
2,069
+443
+27% +$155K ﹤0.01% 7493
2022
Q1 		$711K Sell
1,626
-6,262
-79% -$2.57M ﹤0.01% 8042
2021
Q4 		$3.46M Buy
7,888
+1,789
+29% +$899K ﹤0.01% 4395
2021
Q3 		$3.39M Buy
6,099
+2,551
+72% +$1.28M ﹤0.01% 4693
2021
Q2 		$1.82M Buy
3,548
+2,630
+286% +$1.67M ﹤0.01% 6131
2021
Q1 		$717K Sell
918
-444
-33% -$304K ﹤0.01% 8595
2020
Q4 		$742K Sell
1,362
-587
-30% -$308K ﹤0.01% 7392
2020
Q3 		$893K Buy
+1,949
New +$1.13M ﹤0.01% 6386
2020
Q2 		– Sell
-2,241
Closed -$1.24M – 11097
2020
Q1 		$1.07M Sell
2,241
-1,202
-35% -$653K ﹤0.01% 5260
2019
Q4 		$2M Buy
3,443
+1,936
+128% +$1.36M ﹤0.01% 4337
2019
Q3 		$992K Sell
1,507
-8,934
-86% -$7.43M ﹤0.01% 5706
2019
Q2 		$8.08M Buy
10,441
+4,308
+70% +$3.03M ﹤0.01% 2124
2019
Q1 		$4.33M Sell
6,133
-1,153
-16% -$690K ﹤0.01% 2629
2018
Q4 		$3.41M Sell
7,286
-3,892
-35% -$2.51M ﹤0.01% 2751
2018
Q3 		$9.64M Buy
11,178
+6,246
+127% +$4.51M ﹤0.01% 1984
2018
Q2 		$3.4M Sell
4,932
-3,148
-39% -$1.6M ﹤0.01% 3221
2018
Q1 		$3.6M Sell
8,080
-891
-10% -$432K ﹤0.01% 2968
2017
Q4 		$3.95M Buy
8,971
+5,317
+146% +$2.42M ﹤0.01% 2841
2017
Q3 		$1.8M Buy
+3,654
New +$1.83M ﹤0.01% 4104
2017
Q2 		– Sell
-27,778
Closed -$17.6M – 9955
2017
Q1 		$18.4M Buy
27,778
+24,861
+852% +$13.3M 0.01% 1139
2016
Q4 		$976K Sell
2,917
-185
-6% -$59.4K ﹤0.01% 5587
2016
Q3 		$932K Buy
3,102
+2,486
+404% +$539K ﹤0.01% 4944
2016
Q2 		$107K Buy
616
+287
+87% +$62.5K ﹤0.01% 7993
2016
Q1 		$74K Sell
329
-323
-50% -$96.5K ﹤0.01% 8548
2015
Q4 		$395K Buy
652
+207
+47% +$114K ﹤0.01% 7209
2015
Q3 		$229K Sell
445
-851
-66% -$570K ﹤0.01% 8501
2015
Q2 		$567K Buy
+1,296
New +$501K ﹤0.01% 7370
2015
Q1 		– Sell
-318
Closed -$114K – 10042
2014
Q4 		$114K Buy
+318
New +$102K ﹤0.01% 9144

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's TVRD Position: Q1 2025 in Review

Susquehanna International Group sold out of Tvardi Therapeutics (TVRD) in Q1 2025, closing a stake of 39,262 shares — an estimated $721K sold.

Susquehanna International Group first reported a position in TVRD in Q4 2014 and held it in 37 quarters. The position peaked at $18.4M in Q1 2017. 33 funds tracked by Wall St. Rank hold TVRD as of Q1 2025.

  • Susquehanna International Group reported no remaining Tvardi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 39,262 Tvardi Therapeutics shares in Q1 2025, an estimated $721K.
  • Susquehanna International Group first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 37 quarters.
  • Susquehanna International Group's Tvardi Therapeutics position peaked at $18.4M in Q1 2017.
  • 33 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.